XOMA Royalty Corp (XOMA) Stock Analysis — April 2026 Rating, Price, and Forecast
Company Overview — What Does XOMA Royalty Corp Do?
XOMA Corporation operates as a biotechnology royalty aggregator in Europe, the United States, and the Asia Pacific. The company engages in helping biotech companies for enhancing human health. It acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. The company focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners. It has a portfolio with approximately 70 assets. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California. XOMA Royalty Corp (XOMA) is classified as a small-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO James R. Neal, EMBA and employs approximately 10 people, headquartered in EMERYVILLE, California. With a market capitalization of $394M, XOMA is one of the notable companies in the Healthcare sector.
XOMA Royalty Corp (XOMA) Stock Rating — Hold (April 2026)
As of April 2026, XOMA Royalty Corp receives a Hold rating with a composite score of 38.4/100 and 3 out of 5 stars from the Blank Capital Research quantitative model.XOMA ranks #1,392 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, XOMA Royalty Corp ranks among stocks, placing it in the top 10% of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).
XOMA Stock Price and 52-Week Range
XOMA Royalty Corp (XOMA) currently trades at $36.76. The 52-week high for XOMA is $39.92, which means the stock is currently trading -7.9% from its annual peak. The 52-week low is $18.35, putting the stock 100.3% above its annual trough. Recent trading volume was 0 shares, suggesting relatively thin trading activity.
Is XOMA Overvalued or Undervalued? — Valuation Analysis
XOMA Royalty Corp (XOMA) carries a value factor score of 55/100 in the Blank Capital model, indicating fair valuation relative to historical norms. The trailing price-to-earnings ratio is 27.18x, compared to the Healthcare sector average of 23.63x — a premium of 15%. The price-to-book ratio stands at 4.91x, versus the sector average of 2.75x. The price-to-sales ratio is 9.46x, compared to 1.66x for the average Healthcare stock. On an enterprise value basis, XOMA trades at 9.05x EV/EBITDA, versus 6.34x for the sector.
Overall, XOMA's valuation appears roughly in line with sector benchmarks, suggesting the market is pricing the stock fairly given its current fundamentals and growth trajectory. Neither deep value nor significantly overpriced, the stock occupies a middle ground on valuation.
XOMA Royalty Corp Profitability — ROE, Margins, and Quality Score
XOMA Royalty Corp (XOMA) earns a quality factor score of 32/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is 18.1%, compared to the Healthcare sector average of -43.5%, which is within a healthy range. Return on assets (ROA) comes in at 5.6% versus the sector average of -33.1%.
The operating margin is -71.3% (sector: -66.1%). Net profit margin stands at 17.4%, versus -58.7% for the average Healthcare stock. Revenue growth is running at 527.6% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.
XOMA Debt, Balance Sheet, and Financial Health
XOMA Royalty Corp has a debt-to-equity ratio of 201.0%, compared to the Healthcare sector average of 32.0%. This elevated leverage warrants close monitoring, as it increases the company's sensitivity to rising interest rates and economic downturns. The current ratio is 3.37x, indicating strong short-term liquidity.
XOMA has a beta of 0.80, meaning it is roughly in line with the broader market in terms of price volatility. The stability factor score for XOMA Royalty Corp is 52/100, reflecting average volatility within the normal range for its sector.
XOMA Royalty Corp Revenue and Earnings History — Quarterly Trend
In TTM 2026, XOMA Royalty Corp reported revenue of $44M and earnings per share (EPS) of $1.53. Net income for the quarter was $15M. Operating income came in at $-21M.
In FY 2025, XOMA Royalty Corp reported revenue of $52M and earnings per share (EPS) of $1.53. Net income for the quarter was $32M. Revenue grew 83.1% year-over-year compared to FY 2024. Operating income came in at $11M.
In Q3 2025, XOMA Royalty Corp reported revenue of $9M and earnings per share (EPS) of $0.74. Net income for the quarter was $14M. Revenue grew 29.9% year-over-year compared to Q3 2024. Operating income came in at $-1M.
In Q1 2025, XOMA Royalty Corp reported revenue of $16M and earnings per share (EPS) of $0.06. Net income for the quarter was $2M. Revenue grew 967.9% year-over-year compared to Q1 2024. Operating income came in at $6M.
Over the past 8 quarters, XOMA Royalty Corp has demonstrated a growth trajectory, with revenue expanding from $1M to $44M. Investors analyzing XOMA stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.
XOMA Dividend Yield and Income Analysis
XOMA Royalty Corp (XOMA) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.
XOMA Momentum and Technical Analysis Profile
XOMA Royalty Corp (XOMA) has a momentum factor score of 51/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 20/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 4/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.
XOMA vs Competitors — Healthcare Sector Ranking and Peer Comparison
Within the Healthcare sector, XOMA Royalty Corp (XOMA) ranks #— out of 838 stocks based on the Blank Capital composite score. This places XOMA in the top decile of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.
Comparing XOMA against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full XOMA vs S&P 500 (SPY) comparison to assess how XOMA Royalty Corp stacks up against the broader market across all factor dimensions.
XOMA Next Earnings Date
No upcoming earnings date has been announced for XOMA Royalty Corp (XOMA) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.
Should You Buy XOMA? — Investment Thesis Summary
XOMA Royalty Corp presents a balanced picture with arguments on both sides. The quality score of 32/100 flags below-average profitability.
In summary, XOMA Royalty Corp (XOMA) earns a Hold rating with a composite score of 38.4/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on XOMA stock.
Related Resources for XOMA Investors
Explore more research and tools: XOMA vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare XOMA head-to-head with peers: XOMA vs AZN, XOMA vs SLGL, XOMA vs VMD.